Lupin To Acquire French Pharma Company Medisol For 18 Million Euros
Lupin Ltd.'s Switzerland-based subsidiary, Lupin Atlantis Holding SA, announced its acquisition of French pharmaceutical company, Medisol Lifescience Pvt., on Friday.
The company has agreed to pay a cash consideration of 18 million euros (approximately Rs 160 crore)—of which 14.5 million euros is upfront consideration, and earn-outs are up to 3.5 million euros—to acquire the entire share capital of Medisol, according to its exchange filing.
The deal is subject to necessary approval from the French ministry and is expected to be completed by July 2023.
Founded in 2011, Lyon-headquartered Medisol specialises in generics injectables and is engaged in developing and commercialising its products in pharmacies and hospitals in France.
With this acquisition, Lupin is expected to gain access to Medisol's portfolio of seven injectable products across four therapeutic areas, including pain management, anti-inflammatory, cardiovascular diseases and obstetrics. "This has synergy with Lupin's injectables portfolio and other products," the filing said.
"This acquisition is part of our strategy to expand our presence in the EU and accelerate our injectables franchise in France. France is the second largest market in Europe for injectables with a robust growth," the company said.
Medisol earned revenue of around 7.3 million euros in FY22, 7.1 million euros in FY21 and 5.3 million euros in FY20.
Shares of Lupin closed 0.78% lower on Friday before the announcement of the acquisition, as compared with a 1.13% fall in the benchmark Sensex.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.